Anoro Ellipta

Phase 2Small molecule

AstraZeneca

Anoro Ellipta is one of 48 small molecule programs targeting Lung Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung DiseaseActive, not recruiting

Lung DiseasePhase 2

Active, not recruiting

Competition

Competitive Landscape

74 competitors in Lung Disease

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

—2

Colcrys

Alnylam Pharmaceuticals

Duragesic

1 4

Versed

CConrado Roberto Hoffmann Filho

Inomax

Neurontin

VViatris Specialty LLC

Approved

—7

Sporanox

SSebela Pharmaceuticals Development LLC

Rituxan

1 9

Kalydeco

Vertex Pharmaceuticals

Phase 3

1 10

Mycobutin

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Therapeutics

NCT03002389

Clinical

Trials by Indication[1]

Lung Disease1 trial

A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03645434·73 enrolled

Therapeutics1 trial

Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics

Active, not recruiting·UUniversity of Virginia·Phase 2·NCT03002389·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anoro Ellipta. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anoro Ellipta compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anoro Ellipta. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Anoro Ellipta

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Lung Disease1 trial

Therapeutics1 trial

References

Drug Info

Quick Facts

Related News